Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

Luca Antonioli, Corrado Blandizzi, Fabio Malavasi, Davide Ferrari, G. Haskó

Research output: Contribution to journalEditorial

19 Citations (Scopus)


The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.

Original languageEnglish
Article numbere1216292
Issue number9
Publication statusPublished - Sep 1 2016


  • autophagy
  • CD73
  • immunotherapy
  • monoclonal antibody
  • tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment'. Together they form a unique fingerprint.

  • Cite this